Vapourtec’s Dr Manuel Nuño discusses the future of peptide synthesisers in the latest issue of Speciality Chemicals Magazine. In the article entitled “Continuous flow applied to peptide synthesis – Next generation of synthesisers” [1], Manuel highlights the benefits of synthesising peptides in flow using Vapourtec’s latest reactor, the Variable Bed Flow Reactor (VBFR).
Continuous flow SPPS (CF-SPPS) provides a unique interaction between the solid media and the reagent solutions, improving final peptide purity compared to batch protocols [2].
To reliably synthesise a broad range of peptide sequences, Vapourtec developed the ultimate solid-phase synthesis reactor, the VBFR. The VBFR monitors and controls the packing density of the solid media throughout the synthesis. No matter if it is the synthesis of a 5-mer or a 100-mer peptide, or if it is 2 grams of resin loaded or just 100 mg; the packing density will be accurately controlled, yielding higher purities. Thanks to the high level of automation of our Vapourtec RS-400, when equipped with a VBFR it can be configured to synthesise peptides.
The second benefit of synthesising peptides with Vapourtec is the quality of in-line data. Reactor volume change, along with UV/Vis spectra, allows the user to pinpoint failed couplings and aggregation events as never seen before.
“Vapourtec saw the early adoption of flow chemistry platforms in pharma R&D departments gave a technological advantage to our customers. Thanks to recent publications on CF-SPPS [2]–[4], we have seen a lot of attention growing towards synthetic development of peptides synthesised in continuous flow. We are already supporting customers across the globe who are synthesising peptides with our systems. Thanks to the expertise our R&D and service teams have in CF-SPPS, we can support our customers to gain such technological advantage” said Manuel.
References
To read the article featured in Speciality Chemicals Magazine click here
For more infomation about Vapourtec's variable bed flow reactor click here
